A Randomized Phase 2 Non-comparative Study Of The Efficacy Of Pf-04691502 And Pf-05212384 In Patients With Recurrent Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Gedatolisib (Primary) ; PF 4691502 (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- Sponsors Pfizer
- 02 Dec 2016 This trial was completed in Poland (end date: 2015-12-25), according to European Clinical Trials Database.
- 04 Oct 2016 This trial was completed in Spain (end date: 2015-12-25), according to European Clinical Trials Database.
- 18 Apr 2016 Results published in the Gynecologic Oncology